Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide

de Bono, Johann S., Fleming, Mark T., Wang, Judy S. · Clinical Cancer Research · 2021